Efanesoctocog alfa NCT06940830 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 4

Clinical phase

Recruiting

Recruitment status

250

Planned enrollment

2028-12-01

Primary-completion proxy

Executive view

NCT06940830 evaluates Efanesoctocog alfa in Hemophilia A. The disclosed sponsor is Swedish Orphan Biovitrum AB, the design is Interventional, and the geographic footprint is Czechia, Ireland, United Kingdom, Italy, France, Germany, Spain, Croatia. The first listed primary endpoint is Annualized joint bleeding rate (AjBR) over the prospective observation period., assessed over Enrolment to Month 12, 24 and 36.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06940830 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Hemophilia A landscape. Drug & Asset MCP drug_fetch was queried for Efanesoctocog alfa, while Company & Deal Intelligence MCP organization_fetch was queried for Swedish Orphan Biovitrum AB.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT06940830	Efanesoctocog alfa	Phase 4 / Recruiting	Swedish Orphan Biovitrum AB	Czechia, Ireland, United Kingdom, Italy, France, Germany, Spain, Croatia	Annualized joint bleeding rate (AjBR) over the prospective observation period. Enrolment to Month 12, 24 and 36	2028-12-01
NCT07439055	Emicizumab	Phase 2/3 / Active, not recruiting	Sponsor not reported	Thailand	Annual bleeding rate 8 months	2026-03-01
NCT07285460	Fitusiran	Phase 3 / Recruiting	Sanofi	Saudi Arabia, Canada, Romania, Belgium, United States, China, Turkey, Taiwan Province, Poland, Brazil, Italy, Spain, India	Annualized treated bleeding rate (ABR) in the fitusiran primary efficacy period and in the SOC period Day 85 to Day 421 (fitusiran primary efficacy period); Day -168 to Da…	2029-08-04
NCT07238816	Inno8	Phase 1 / Completed	Novo Nordisk A/S	United States	AUC0-∞: the area under the plasma Inno8 concentration-time curve from time 0 to infinity after a single oral dose From baseline (Day 1) to day 17	2026-05-08
NCT07226206	SPK-8011	Phase 1/2 / Recruiting	Roche Holding AG	United States	Incidence of participants with adverse events (AEs) Up to approximately 5 years	2032-04-30

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT06940830 is a Phase 4, recruiting study with 250 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “Annualized joint bleeding rate (AjBR) over the prospective observation period.” over “Enrolment to Month 12, 24 and 36.” No additional primary-endpoint description was returned in the selected field set.

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 250 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Hemophilia A. These records do not establish direct evidence for NCT06940830 unless the registration number matches.

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inh…

Phase 3; n=2; No numerical result field reported Source: https://clinicaltrials.gov/ct2/show/results/NCT05695391

ISTH 2026 （Mim8）3 A FRONTIER ，

3; n=426; AE(Injection-site reactions (ISRs)) = 2.0 % ; AE(Injection-site reactions (ISRs)) = 1.8 % Source: https://www.novonordisk.com.cn/content/nncorp/cn/zh_cn/news---media/2026071401.html

EXPANDING ACCESS TO HEMOPHILIA CARE : SIGNIFICANT REDUCTION IN BLEEDING WITH LOW-DOSE EMICIZUMAB PROPHYLAXIS IN A PROSPECTIVE REAL-WORLD COHORT .

Not Applicable; n=27; ABR = 3.9 point ( 2.1) Source: https://library.ehaweb.org/eha/2026/eha-2026/4209009/aditi.malji.expanding.access.to.hemophilia.care.significant.reduction.in.html

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

No exact Drug & Asset MCP profile was returned for the protocol wording “Efanesoctocog alfa.” The report therefore avoids inferring modality, target or global development stage from the name alone.

No exact Company & Deal Intelligence profile was returned for Swedish Orphan Biovitrum AB. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Efanesoctocog alfa is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT06940830
Protocol source: https://clinicaltrials.gov/study/NCT06940830
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.

Efanesoctocog alfa in Hemophilia A is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Annualized joint bleeding rate (AjBR) over the prospective observation period. and 2028-12-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP